Physician profile
Ece Demir
NPI 1609606573
$2,799.87
in general payments reported to CMS, 2019-2025
34 companies · $2,800 in 2025
The $2,800 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $2,800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,349 · Education: $451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,348.90 |
| Education | $450.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $297.99 | 2025 | |
| Beone Medicines USA, INC. | $297.82 | 2025 | Brukinsa |
| Astellas Pharma US INC | $204.41 | 2025 | Xtandi |
| Merck Sharp & Dohme LLC | $183.09 | 2025 | Keytruda, Welireg, Keytruda Qlex |
| Caris Mpi, INC. | $169.33 | 2025 | Mi Cancer Seek |
| Tempus Ai, INC | $154.69 | 2025 | Xt Cdx |
| Glaxosmithkline, LLC. | $138.50 | 2025 | Jemperli, Zejula, Ojjaara |
| Astrazeneca Pharmaceuticals LP | $137.33 | 2025 | Tagrisso |
| Janssen Biotech, INC. | $115.29 | 2025 | Carvykti, Rybrevant, Talvey |
| Pfizer INC. | $109.69 | 2025 | |
| Celgene Corporation | $79.90 | 2025 | Reblozyl |
| Daiichi Sankyo INC. | $78.07 | 2025 | Datroway, Enhertu |
| Genzyme Corporation | $73.14 | 2025 | |
| Geron Corporation | $62.08 | 2025 | Rytelo |
| Sobi, INC | $58.12 | 2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $54.20 | 2025 | Monoferric |
| Lilly USA, LLC | $53.67 | 2025 | Verzenio, Jaypirca |
| Amneal Pharmaceuticals LLC | $52.72 | 2025 | Alymsys |
| Incyte Corporation | $51.84 | 2025 | Jakafi |
| Array Biopharma INC | $46.54 | 2025 | Braftovi, Mektovi, Lorbrena |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.06 | 2025 | |
| Stemline Therapeutics INC. | $39.92 | 2025 | Orserdu |
| Novocure INC. | $34.44 | 2025 | Optune Lua (Novottf-200t) |
| Pharmaessentia USA Corporation | $28.40 | 2025 | Besremi |
| Novartis Pharmaceuticals Corporation | $26.88 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.01 | 2025 | Iclusig |
| Bayer Healthcare Pharmaceuticals INC. | $25.88 | 2025 | |
| Azurity Pharmaceuticals, INC. | $24.46 | 2025 | Danziten |
| Immunocore Limited | $24.41 | 2025 | Kimmtrak |
| Fennec Pharmaceuticals, INC. | $23.42 | 2025 | Fyarro |
| Lundbeck LLC | $22.69 | 2025 | Vyepti |
| Spectrum Pharmaceuticals INC. | $22.41 | 2025 | Rolvedon |
| Iovance Biotherapeutics, INC. | $21.38 | 2025 | Amtagvi |
| Ipsen Biopharmaceuticals, INC | $19.09 | 2025 | Onivyde |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ece Demir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.